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ABSTRACT OF THESIS

EFFECTS OF IMAGE CONGRUENCY ON PERSUASIVENESS AND RECALL
IN DIRECT-TO-CONSUMER PRESCRIPTION DRUG ADVERTISING

Although direct-to-consumer (DTC) prescription drug advertising is
regulated by the U.S. Food and Drug Administration, content analyses (BairdHarris, 2009; Frosch, Krueger, Hornik, Cronbolm, & Berg, 2007; Kaphingst,
DeJong, Rudd, & Daltroy, 2004; Wilkes, Bell, & Kravitz, 2000) and other studies
(Davis, 2000, 2007) have suggested that advertisers may not disclose drug risks
to the same extent that they describe drug benefits. This study builds on
previous studies by Baird-Harris and Smith and Shaffer (2000) and aims to test
the relationship between image congruency in televised DTC advertisements,
recall of risks and benefits, and perceived ad persuasiveness. Advertisements
for Nexium, Advair, and Lunesta were shown to college students in either their
original (i.e., image incongruent) or modified (i.e., image neutral) form. In general,
risks were easier to recall with image neutral advertisements (which were
considered to be less persuasive), although results were not statistically
significant. Gender had a significant interaction effect, suggesting that males and
females process risks differently depending on images in a DTC advertisement.
Despite its lack of significant findings, this study explores an underdeveloped
area of research and provides a model for future studies.
KEYWORDS: Direct-to-Consumer Advertising, Fair Balance, Image
Congruency, Elaboration Likelihood Model, Drug
Risks
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Chapter One: Introduction
In recent years, direct-to-consumer (DTC) advertisements for prescription
drugs have become ubiquitous. Between 1996 and 2005, total spending on DTC
advertising increased 330% (Donohue, Cevasco, & Rosenthal, 2007). In 2004,
the average American saw approximately 40 minutes of DTC advertisements
each week; in contrast, Americans spend, on average, only 15 minutes speaking
with a primary-care physician in an entire year (Brownfield, Bernhardt, Phan,
Williams, & Parker, 2004).
However, DTC advertising is surrounded by controversy. Supporters
argue that DTC ads educate the public by exposing them to health conditions
and empowering them to seek additional health information. Additionally,
proponents say that DTC advertising does not lead to inappropriate use of the
advertised drugs because patients still need a physician prescription to get these
drugs. Conversely, opponents of DTC advertising contend that advertisements
encourage patients to ask doctors for newer, higher-priced drugs, some of which
may be inappropriate or inferior to existing treatments. Also, DTC advertising
can harm the physician-patient relationship because patients may question
physician authority (Kaiser Family Foundation, 2001). DTC advertising may also
oversimplify complex information, thus misleading an American public with
generally low health literacy (Baird-Harris, 2009; Kaphingst & DeJong, 2004).
Wilkes, Bell, and Kravitz (2000) agreed with these sentiments: “It is contradictory
to have a category of drugs called ‘prescription,’ made available through those

with specialized training, yet allow those same drugs to be marketed to persons
who lack that specialized knowledge” (p. 114).
DTC advertising has the potential to influence both patient and physician
decision making. A 2010 study by AARP showed that 78% of Americans over
age 18 recalled encountering televised DTC ads for prescription drugs, and of
those who eventually asked a physician for a specific drug, 68% received either a
prescription or a free sample (Brown, 2010). These statistics illustrate a
movement toward increasing patient responsibility for prescription medication,
and it is certainly plausible that televised DTC ads are a driving force behind this
trend. Thus, evaluating advertisements and their effects on people is important.
The way the information in a DTC ad is presented may change
consumers’ perceptions and knowledge of the drug. Others (e.g., Baird-Harris,
2009) have shown that images shown during presentation of risks (i.e., drug side
effects and contraindications) are often incongruent with voiceovers; that is, while
the voice track says one thing, the pictures say another. The potential effects of
this incongruency, though, have yet to be studied. This study will attempt to
determine whether incongruent imagery affects recall of risks and benefits and
perceived persuasiveness of an advertisement. To do so, advertisements will be
manipulated to contain either incongruent or neutral images during presentation
of risks, and differences between two groups of undergraduate students will be
examined.
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Direct-to-Consumer Advertising
Currently, the United States and New Zealand are the only countries that
allow DTC advertising for prescription drugs. And U.S. pharmaceutical
companies are becoming more aggressive with their DTC efforts: in 2009,in the
midst of an economic recession, pharmaceutical companies spent $4.3 billion on
DTC advertising efforts, a figure that more than doubled 1999 numbers (Kaiser
Family Foundation, 2010).
According to Bradley and Zito (1997), there are three categories of DTC
advertising. First, health-seeking advertisements educate the public about a
health problem and encourage them to seek physician assistance without
necessarily naming a specific product or treatment method. Second, reminder
advertisements give minimal information about a drug but do not mention the
drug’s use, effectiveness, or safety. Third, product-specific advertisements focus
on a drug by name, describe its use(s), and discuss its effectiveness and safety.
Most DTC advertisements are product-specific advertisements; for this reason,
most research on DTC advertising has focused on this type of ad. In keeping with
DTC advertising research, this study will use product-specific advertisements as
well.
As previously mentioned, an inherent conflict exists with DTC advertising.
Although it can help to educate the public by providing information on health
conditions and treatment, its true purpose may be to simply help companies
promote their products. In order to maintain a balance between these two
competing interests, the U.S. Food and Drug Administration has set forth
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regulations for DTC advertising. Whether these regulations serve the better
interest of the public health, though, is up for debate.
A “Fair Balance”?
Regulations for prescription drug advertisements are included in the
Federal Food, Drug, and Cosmetic Act. These requirements attempt to ensure
that DTC advertisements are not false or misleading and that a “fair balance”
exists between disclosure of risks and benefits (FDA, 2009).
DTC advertisements must include information about drug effectiveness,
side effects, and contraindications; this information is often referred to as a “brief
summary.” Because space for information varies depending on advertising
channel, different requirements exist for print and broadcast DTC advertising.
Print DTC ads must include the brief summary, often containing information
directly from the product’s labeling. However, fitting an entire brief summary into
a time-limited broadcast DTC advertisement would be difficult. For this reason,
the FDA only requires that major risks be disclosed in these advertisements; this
requirement is known as the “major statement.” Additionally, sponsors of
broadcast DTC advertisements must also make an “adequate provision” to allow
for the dissemination of additional materials in conjunction with the broadcast
advertisement. The adequate provision requirement forces DTC advertisers to
direct consumers to at least one of four sources: a toll-free telephone number,
Internet web site, specific print advertisement (e.g. “See our ad in Ladies’ Home
Journal.”), or physician or pharmacist (FDA, 2009).
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However, Davis (2000) noted some flaws with FDA regulations. He
argued that advertisers can satisfy the FDA’s requirements without fully
disclosing drug side effects: “Advertisers must present a balance of drug benefits
and risks (side effects). They are, however, under no compulsion to report all of
[sic] side effects or to even report all major side effects” (p. 351; italics original).
So, many broadcast DTC advertisements often contain what Davis called
“incomplete risk statements.” Davis said that in order for fair balance to be
satisfied, consumers must fully understand the likelihood of suffering side effects
and be able to make an educated decision when considering the context of
anticipated drug benefits. However, previous content analytic research has
suggested that full comprehension of drug risks and benefits may be difficult for
consumers.
Indeed, several researchers have conducted content analyses of direct-toconsumer advertising. In general, results suggest that although both benefits
and risks are often mentioned, they are often communicated differently. These
differences may influence consumer comprehension.
Language Use and Presentation of Information in DTC Advertising
Use of text. In a 2000 content analysis of televised DTC ads, Wilkes et al.
noted that headings and subheadings usually related to benefits of the drug, but
side effects were often buried in the advertisement narrative. Kaphingst et al.
(2004) found that advertisements satisfied adequate provision because they
provided references to other sources of information, but this information was
almost exclusively presented in text. Eighty-three percent of advertisements also
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contained some text that the authors judged difficult to read, although the hardto-read text usually discussed supplemental information (e.g., generic drug
name) rather than specific risks and benefits. Overall, textual elements of
broadcast DTC advertisements generally favor benefit information over risk
information.
Risk-benefit language use. In general, research suggests that
advertisements use more complex language when discussing risks than when
discussing benefits. Day (2006) argued that “information can be physically
present yet functionally absent” (p. 9), implying that even though viewers of DTC
advertisements may receive information, they may not always be able to interpret
and use it. Day found that in a sample of DTC advertisements, information on
benefits was given at a 6th grade reading level but information on risks was given
at a 9th grade reading level.
Also, Day (2006) showed that when study participants were asked to
report benefits and side effects after viewing three DTC advertisements (Paxil,
Nasonex, and Orthotricyclen), they were 80% correct when listing benefits but
only 20% correct when listing risks. Day did recognize, though, that the
advertisements used in the experiment contained more side effects than benefits,
so differences in recall could have been affected by information overload. Still,
Day’s findings suggest that viewers of DTC advertisements may not be able to
comprehend risks and benefits equally. Similarly, Kaphingst, Rudd, DeJong, and
Daltroy (2005) found that after exposure to three different DTC advertisements,
50 low-literacy adults were able to recall benefit information more easily than risk
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information. These findings suggest that comprehending and recalling risks and
benefits may depend on complexity of language and individual literacy levels.
Pacing and timing of voice track. Kaphingst et al. (2004) also found
imbalances between presentations of risks and benefits in pacing. On average,
benefit facts were presented at a rate of 0.54 facts per second, whereas risk
facts were presented at a rate of 0.78 facts per second.
Additionally, Frosch et al. (2007) and Wilkes et al. (2000) both found that
side effects were generally presented in the latter half of an advertisement, but
the final statement of an ad usually listed a benefit; thus, recall of risks may be
difficult because of primacy and recency effects (see Miller & Campbell, 1959).
Given these reported issues, this study first hypothesizes that when timing
and pacing are considered in combination with the use of text and language
choice, it is likely that:
H1: Participants will recall benefit information more easily than risk
information.
The Elaboration Likelihood Model
Petty and Cacioppo’s (1986) elaboration likelihood model (ELM) proposes
that there are two routes for message processing: central and peripheral. In the
central route, a person thoroughly and thoughtfully considers a message; in
contrast, those taking the peripheral route rely on simple cues in the persuasion
context. To process information centrally, persons require both motivation and
ability.
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Ability to comprehend risks and benefits on an equal level, though, may be
compromised because of some tactics used by DTC advertisers. This concept is
demonstrated by the previously stated arguments that risks are presented more
quickly (Kaphingst et al., 2004), with more complex language (Day, 2006), and
sandwiched between (Kaphingst et al., 2004; Wilkes et al., 2000) benefits.
Difficulty in recalling risks (as in Kaphingst et al., 2005) may be illustrative of a
lack of ability to process and comprehend. Even if motivation is high to process a
message centrally, lack of ability can inhibit doing so.
When people do not have the ability to process information thoroughly, the
ELM suggests that they are more likely to rely on peripheral cues for information.
One example of a peripheral cue would be imagery, but in DTC advertising,
imagery may not always be accurate.
Use of Images in DTC Advertising
Images in DTC advertising can play a powerful role in developing
consumers’ perceptions of drugs. According to Wilkes et al. (2000), “Powerful
yet subtle product claims can be made visually. When DTC advertising
misleads, it often does so through visual persuasion” (p. 124).
Findings from Cline and Young’s (2004) content analysis of print DTC
advertisements supported the idea that visual images may be misleading. For
example, Cline and Young found that in 93.1% of advertisements for arthritis,
advertisements showed active people engaged in physical activity. Given the
nature of arthritis, these advertisements clearly only visually emphasize the
benefits of the advertised drugs. However, Cline and Young’s study used only
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print ads; because print ads only allow for one static image, it makes sense that
advertisers would choose an image that enforces the benefits rather than
negatives of a drug. Still, the following question arises: Does using only a positive
image to represent all information about a drug satisfy fair balance?
Although Cline and Young’s (2004) analysis used print ads, similar results
have been found in content analyses of broadcast ads. In Kaphingst et al.’s
(2004) study, only positive or neutral images were shown in DTC ads, even when
side effects of drugs were being discussed. Similarly, Baird-Harris (2009) found
that 95.3% of the images accompanying drug benefit information were congruent
with the information being discussed. In contrast, only 11.8% of images
presented during risk information disclosure matched the voice track and/or
superscript/subscript text. Kaphingst and DeJong (2004) made a logical assertion
about voice track-image incongruency: “An ad with contradictory visual and audio
messages that minimize risk information compared with benefit information fails
to provide fair balance” (p. 146).
Most likely, these images contribute to a lack of ability to thoroughly
process information; if they differ from audio information, then they may serve as
a distraction. This idea was reflected in a study involving vividness congruency
by Smith and Shaffer (2000). Smith and Shaffer found that message processing
can be reduced by adding vivid but incongruent images to a message. Their
study did not use pictures; rather, it used “vivid imagery,” or language that
provided a readily-accessible image (e.g., a “foaming martyr”). The authors
echoed an argument by Frey and Eagly (1993) by suggesting that:
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…vivid presentations may elicit high amounts of elaborate
imagery that may be tangential or even irrelevant to the message
itself. By occupying the individual’s working memory with
information that is irrelevant to the message, a vivid message
would make it more difficult for the individual to process and
remember the message arguments. Thus, vivid elements can
reduce the ability to process a message—that is, if the images
and thoughts brought to mind are irrelevant. (p. 770)
So, Smith and Shaffer’s (2000) study showed that people had a more
difficult time processing the message’s arguments when presented with language
that could potentially evoke irrelevant vivid images. But, according to Kaphingst
et al.’s (2004) content analysis, DTC advertisers go one step further—instead of
using language that may bring irrelevant images to mind, they only provide
irrelevant images to accompany advertising language when talking about side
effects. If Smith and Shaffer’s findings can be applied to DTC advertising, then
people would likely have a difficult time processing side effects when presented
with incongruent images.
If advertisements contained congruent—or at least neutral—images during
presentation of risks, it is likely that the message in the voice track will be easier
to process. DTC advertisers are unlikely to show images during risks that are
completely congruent—a possible example might entail showing a person
vomiting when talking about nausea. However, it is possible for them to use
neutral images; for example, a “talking head” (i.e., static visual of actor speaking)
or screen with drug name may be appropriate. Given Smith and Shaffer’s (2000)
findings, this study also posits that:
H2: Participant will have more difficulty recalling risks when advertising
images presented are incongruent as compared to neutral.
10

Persuasion in DTC Advertisements
AIDA Model. On a macro level, DTC advertisements relate to hierarchical
advertising theories. In general, several past models have been used to describe
persuasiveness in advertising. The first, and foundational, among them was
Strong’s (1925) AIDA model. The AIDA model encompasses four stages—
attention, interest, desire, and action—each of which forms the acronym AIDA.
AIDA is an early hierarchical model of steps that occur when a person interacts
with an advertisement. First, the advertisement must gain the consumer’s
attention by introducing the product. Then, the advertisement must interest the
consumer by explaining features, pros, and cons. After the consumer becomes
interested, the next step involves invoking desire for the product. The final stage,
action, refers to the “buying” of the marketing product. Subsequent models
(AIDAS, CAB, and TIERA) have their foundations in AIDA.
Like all advertisements, DTC ads relate to AIDA (Strong, 1925). The three
kinds of DTC ads defined by Bradley and Zito (1997) fit distinctly into AIDA. Both
“reminder” and “health-seeking” advertisements satisfy the attention component,
while “product-specific” advertisements satisfy interest and action by describing
the specific drug and telling people to ask their doctors about the product. Ideally,
these advertisements also attempt to evoke desire for the drug by presenting it in
a pleasing manner. Logically, DTC advertisers incorporate elements from
hierarchical models, such as AIDA.
Elaboration Likelihood Model. When breaking down DTC
advertisements, it becomes apparent that the individual characteristics (e.g.,
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voice track, images, text) relate to the elaboration likelihood model (ELM; Petty &
Cacioppo, 1986). To revisit the ELM, people rely on peripheral cues to process
messages when they lack either motivation or ability to process them centrally.
With DTC advertising, central processing may be difficult, particularly with risk
information. Thus, peripheral cues such as images may not only be the primary
source of information but also the main factor behind persuasion. If images
downplay the risks of a drug but emphasize its benefits, it is possible that people
will hold a more favorable attitude toward that drug (logically, people will hold a
favorable attitude toward a product when benefits outweigh risks). While others
have examined images in DTC advertisements through content analyses, no one
has looked at image congruency’s effect on persuasiveness. However, it is
reasonable to hypothesize that manipulation of images could also affect
advertisement persuasiveness. Because incongruent images during audio
presentation of risks most likely emphasize benefits over risks, it is hypothesized
that:
H3: Participants will find advertisements with incongruent images during
presentation of risks to be more persuasive than those containing neutral
images.
Study Rationale
Many of studies previously cited in this paper did not employ a specific
theory to guide their work (see e.g., Kaphingst et al., 2004; Wilkes et al., 2000)
because they were exploratory content analyses. However, some theories may
be useful when examining image use in DTC advertising. Cline and Young
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(2004) mainly used social learning theory (Bandura, 1977) when analyzing
modeling in DTC images. However, both Cline and Young and Smith and
Shaffer (2000) discussed the use of dual process models, such as the ELM
(Petty & Cacioppo, 1986) and the heuristic-systematic model (HSM; Chaiken,
Liberman, & Eagly, 1989). Baird-Harris (2009) approached her study using
semiotics analysis (Gall, Gall, & Borg, 2003). The previously stated hypotheses
are based on the ELM, as it relates to ability to process information thoroughly.
Health Literacy Implications
Health literacy, defined as “the degree to which individuals have the
capacity to obtain, process, and understand basic health information and
services needed to make appropriate health decisions” (Institute of Medicine,
2004), is important to consider when examining portrayals of risks and benefits in
televised DTC advertisements. Ratzan and Parker (2006) found that people with
basic or below basic health literacy were more likely to get health information
from television than print. Baird-Harris (2009) argued that people with low health
literacy may rely more on images to understand health information when
language is too complex. This overreliance on images presents a problem
because, as previously mentioned literature suggests, television DTC advertising
may be especially difficult to comprehend because it sometimes combines
language with incongruent images (Baird-Harris, 2009; Kaphingst et al., 2004).
So, those people who have the hardest time comprehending health information in
general are attempting to do so using broadcast advertisements which can be
considered more complex than print given the greater amount of stimuli. For this
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reason, examining the effects of incongruent images in television DTC
advertisements has clear health literacy implications.
Gap in the Literature
Even with Baird-Harris’s (2009) study, literature addressing image
congruency and fair balance in televised DTC advertising is lacking. The use of
content analysis when examining fair balance in DTC advertising is common;
however, Davis and Meader (2009) argued that content analysis alone is
insufficient.
However, Davis and Meader’s (2009) study only used audio or textual
advertisements; that is, no television advertisements were used. Yet, according
to Frosch et al. (2007):
…television advertising now comprises most of the consumerdirected prescription pharmaceutical marketing expenditures.
Previous research has examined print ads, but unlike print ads,
television ads combine visual imagery, music, and spoken words
to create complex stories that may provide more information and
appeal to a wider range of consumer emotions. (p. 7)
Clearly, more attention needs to be paid to televised DTC advertisements.
Although many studies have shown that DTC advertisements may not
have fair balance (see e.g., Baird-Harris, 2009; Cline & Young, 2004; Kaphingst
et al., 2004), they do not take into consideration the viewer’s understanding of
the integration between visual and verbal elements. Baird-Harris recognized that
her study did not test for viewer comprehension of advertisements but rather just
showed that risk and benefit messages in televised DTC advertisements lacked
functional equivalence. Said Davis and Meader (2009): “We believe an
evaluation of fair balance should not only include an analysis of what is in the ad
14

but additionally should reflect how consumers interpret the ad….consumer
response and interpretation take precedence over a literal analysis or
examination of an advertisement’s content” (p. 58; italics original). This study will
attempt to address this gap in the literature by testing consumer recall in relation
to incongruent images presented during drug risks as well as examining
perceived ad persuasiveness. In this way, it follows the recommendations set
forth by both Baird-Harris and Davis and Meader.
Despite the points made by Davis and Meader (2009), a content analysis
still needed to be conducted to help select appropriate advertisements for the
experiment. This analysis attempted to replicate those done by others (e.g.,
Baird-Harris, 2009), although it also included the element of persuasiveness.
Doing such a study could help guarantee that the original versions of the
advertisements were indeed image incongruent, and also help to try to control for
other factors between the ads used, such as persuasiveness. This content
analysis, known as “Study One” is covered in Chapters Two through Five. The
subsequent experiment, known as “Study Two” is covered in Chapters Six and
Seven with an overall discussion in Chapter Eight.

15

Chapter Two: Study One Background
A content analysis (known as “Study One”) was conducted to examine
advertisements for the 15 most prescribed drugs that were advertised on
television. Several constructs were coded, including source characteristics,
image congruency, and persuasiveness as related to Strong’s (1925) AIDA
model.
Hypotheses and Research Questions
Based on the information presented in the literature review in Chapter
Two, benefits and risks are usually conveyed differently in DTC advertisements.
The use of text, as described by Wilkes et al. (2000) and Kaphingst et al. (2004)
led to the formation of the following hypothesis (distinguished from experimental
study hypotheses by initials “CA” for “Content Analysis”):
CA H1: Advertisement text will contain more benefit information than risk
information.
This hypothesis also raises the following questions about text congruency (see
operationalization on page 21):
CA RQ1: Are there varying degrees of text congruency in presentation of
risks and benefits?
CA RQ2: Do differences in text congruency for risks and benefits affect
advertisement persuasiveness?
Similarly, is it likely that findings about packing of risks and benefits in
voice track would mirror those in the study by Kaphingst et al.’s (2004):
CA H2: Risk information will be presented more quickly than benefit
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information.
To review, both Wilkes et al. (2000) and Frosch et al. (2007) found that
benefits tend to be presented during the first part of an advertisement while risks
are presented in the second half. For this reason, the following hypothesis was
formed:
CA H3: Benefit information will be presented before risk information.
Little research has examined voiceover, narrator gender, and resulting
advertisement persuasiveness. But, change in voice from benefits to risks may
also affect persuasiveness. Because this area has not been explored, the
following research question was posed:
CA RQ3: Do differences in voice tracks affect advertisement
persuasiveness?
Evidence presented by several studies (e.g., Baird-Harris, 2009;
Kaphingst & DeJong, 2004) suggests that an incongruency exists with images
used during presentation of risks. Thus, one can expect that:
CA H4: Images presented during benefit information will be congruent
with the voice track, but images presented during risk information will be
incongruent with the voice track.
As suggested in the literature review (as well as by researchers such as
Kaphingst and DeJong (2004)), a corollary hypothesis exists expecting that using
incongruent images may lead to more persuasive advertisements, as risks may
be minimized:
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CA H5: Advertisements will be perceived as more persuasive when
images presented during risks are incongruent.
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Chapter Four: Content Analysis Methods
Selection and Sampling
Drugs included in this phase of the study consisted of the 15 most
frequently prescribed drugs in 2010 (“Pharmaceutical Sales 2010”, 2011; see
Appendix A) that were advertised on television (actual rankings for the 15 drugs
were 1-40, but some drugs, such as OxyContin, are frequently prescribed but not
advertised on television). These criteria identified the following drugs, all of
which were used in this preliminary analysis: Abilify, Advair, Aricept, Celebrex,
Crestor, Cymbalta, Lipitor, Lunesta, Lyrica, Nasonex, Nexium, Plavix, Seroquel,
Spiriva, and Viagra (for treatment conditions, see Appendix B). To gather the
ads for these drugs, a 10% sample of all television mentions for these drugs was
pulled from a search of broadcast channels (ABC, NBC, CBS, FOX, and CW) for
the calendar year 2010.
Advertisement Analysis
The sample of 51 ads was double-coded for image congruency during
presentation of risks, number of risks and benefits presented, length of risk and
benefit presentation voiceover, superscript/subscript text, part of ad where risks
and benefits were presented, drug spokespeople, source credibility and
similarity, target audience, and persuasiveness (see Appendix D for the DTC Ad
Coding Protocol). A second coder was used for reliability purposes. All
advertisements were double-coded and coders achieved sufficient intercoder
reliability (Cohen’s kappas ranged from .75 to 1.00, with seven variables
receiving scores of 1.00), except for source experience (kappa= .619) and source
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likeability (kappa= .673), which approached an acceptable level of intercoder
reliability. Coding disagreements were resolved through discussion between the
two coders.
Advertisement Definitions
For this analysis, we coded for visual and voice track consistency as
related to risks and benefits (see Appendix C for coding definitions). Definitions
were loosely based on Baird-Harris (2009):
Benefits. Benefits were defined as anything discussing the drug use and
its effectiveness in reducing symptoms for its applicable condition. Additionally,
any advantages listed over other medications or testimonials from actors or other
spokespeople were considered presentation of benefits.
Risks. Risks were defined as any negative effects associated with the
drug, including side effects, contraindications (i.e., conditions which make a
treatment unadvisable), warnings, drug interactions, and mentions of instances in
which one should seek medical attention if taking the drug.
Target audience. For target audience, we coded for gender and age
most likely to be affected by the health condition and thus be potential
consumers for the drug. This information was used when coding for lifestyle and
demographic similarity.
Voice track. Voice track included any words spoken during the
advertisement and included both actor testimonials and narration of risks and
benefits. The voiceover content was verified using closed captioning transcripts.
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We coded for presentations of benefits and risks in the voiceover track.
However, some information in the voice track did not discuss risks or benefits.
General information about the drug not relating to risks or benefits including drug
name, drug class, or discussion of the health condition it treats (e.g., incidence
and prevalence) was not included in the coding, nor were any promotional
messages, such as “Lipitor is produced by Pfizer.”
Primary visual. The primary visual was the on-screen image, including
“visual images of actors, animals, or landscapes; animation; a screen that
contains all text or text that appears over an abstract, out-of focus or blank
background” (Baird-Harris, 2009, p. 8).
Text. Text can be presented a few different ways in DTC advertising.
However, all kinds of text were coded simultaneously. The first kind, superscript,
was any larger text on the screen that was superimposed on top of the image.
This included anything other than drug name or the name of the company that
produces the drug (both of these are often represented using logos). In
comparison, subscript text was anything placed at the bottom of the screen
(either on top of the image or on a colored bar). Subscript was usually presented
in small text and looked similar to subtitles.
Congruency. Similar to Baird-Harris (2009), consistency between voice
track, on-screen text, and visual was examined. Baird-Harris chose to code for
all three of these variables at the same time, separating each second of the
advertisement. However, the current analysis considers advertisements more
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holistically; text congruency and image congruency were measured
simultaneously the “benefits” and “risks” segments of the ads.
Text congruency. Due to space issues, a great deal of information was
only presented in voiceover, but we compared on-screen text with voiceover
content. Degree of text congruency was measured based on whether or not risk
and benefit information presented in on-screen text was also present in the voice
track. The number of risks or benefits in the voice track was counted, as were
risks and benefits in on-screen text. The number of times new information (i.e.,
not in voice track) was presented in text was noted for both risks and benefits.
Then, the number of “unique” risks or benefits presented in text was divided by
the overall number of risks or benefits to determine a “text congruency”
percentage.
Image congruency. Congruency referred to the agreement between
visual and voiceover. Voice track and visuals were deemed congruent if they
represented the ideas expressed in the voice track. For example, if an
advertisement discussed risks and side-effects of a drug while showing a person
being active or living symptom-free, that part of the advertisement was coded as
incongruent. A visual with a blank or out-of-focus background with drug name
and text was considered neutral. Similarly, if actors were shown with smiling
faces during presentation of risks, that part of the advertisement was considered
incongruent. A visual with a blank or out-of-focus background with drug name
and text was considered neutral, as were any “talking heads” (i.e., single shot of
actor talking). Thus, image congruency was coded as follows: (1) congruent (i.e.,

22

positive when discussing benefits, negative when discussing risks); (2) neutral; or
(-1) incongruent (i.e., negative when discussing benefits, positive when
discussing risks).
Persuasiveness Definitions
We coded for source characteristics and elements related to Strong’s
(1925) AIDA model (See Appendix C for coding definitions).
Risk-to-benefit ratio. For each advertisement, risks and benefits were
counted and a ratio was calculated. Percent of advertisement time spent
discussing risks or benefits was calculated as well.
Source characteristics. For each actor, we coded for role,
trustworthiness, expertise, dynamism, celebrity status, attractiveness, and
demographic and lifestyle similarity to target audience. Outside of roles, sources
with high levels of these characteristics are often perceived to be more
persuasive (O’Keefe, 2002; Salmon & Atkin, 2003; Stiff & Mongeau, 2003).
Actor role. For role, actors (i.e., characters in the advertisement) could
be placed into one of three roles: primary, secondary, or background. Primary
and secondary actors either gave testimonials or were the focal point in a primary
visual at some point during the advertisement.
Trustworthiness. Based on the dimensions from Salmon and Atkin
(2003), characters that seem like they are generally honest, telling the truth, or
have little to gain by telling or showing others their experiences were coded as
trustworthy.
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Expertise. Borrowing from Salmon and Atkin (2003), expertise was
considered based upon training and experience. High training refers to any
character appearing to have specialized knowledge, such as a doctor or
pharmacist. Sources were considered to have experience when they had taken
the drug (or acted as if they had).
Dynamism. Dynamism, or sociability, was judged based on Bowers’s
(1965) speaking styles. Sources were considered dynamic or sociable when
they exhibited an “extroverted” speaking style, defined as using highly fluent and
rapid speech, few vocalized pauses, and appropriate vocal emphasis.
Celebrity status. We coded for celebrity status by categorizing sources
as either a recognizable celebrity figure or voice or not (yes-no for celebrity
presence).
Likeability. While we coded for general perceptions of likeability
(“likeable,” “not likeable,” and “unsure”), we also looked at demographic and
lifestyle similarity (assessed as a similar lifestyle portrayal) as aspects of
likeability. Although not an exact proxy for attitudinal similarity, lifestyle similarity
can be used as a quasi-proxy as it comprises one possible dimension of
attitudinal similarity. While not a perfect indicator of attitudinal similarity, gauging
this dimension via visual coding of DTC ads is not feasible as attitude and
personal beliefs of characters cannot be reliably determined given the limited
information about characters’ thoughts presented in the DTC advertisements.
Advertisement persuasiveness. To measure advertisement
persuasiveness, we looked at Strong’s (1925) AIDA model, which has long
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provided the foundation for other persuasiveness measures in advertising.
Although the AIDA model is somewhat simplistic and produced little variation in
results (it is reasonable that product-specific advertisements would not merely
satisfy attention, but promote interest, desire, and action), it was chosen because
of the double-coding in this study. Because we used two coders, we needed to
use a measure of persuasiveness with which we could assess reliability; ratings
on a scale would have likely differed. We operationalized the constructs as
follows:


Attention (cognitive stage activity): Introduce a (new) product or
new use of an existing product (not focus on its use features, just
generates attention or buzz for it without talking about how it works;
a teaser)



Interest (affective stage activity): Does it explain the features of the
product and/or its use, application, benefits, and consequences
(risks)?



Desire (affective stage activity): Does the ad attempt to create
positive attitudes, disposition towards the product, desire, liking,
preference?



Action (behavioral stage activity): Does the ad have a call to action,
asking the consumer to buy the product, or to ask a doctor about it?

Persuasiveness Scoring
Because one hypothesis (CA H5) and two research questions (CA RQ2,
CA RQ3) required an objective measure of ad persuasiveness, a composite
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score was created. First, a composite score for the primary actor was calculated
based on presence or absence (1= present; 0.5= unsure, 0= absent) for each of
the following source characteristics: trustworthiness, expertise, experience,
sociability, celebrity status, likability, demographic similarity, and lifestyle
similarity. All of these characteristics were summed for all primary or secondary
actors in the ad and the total was divided by number of primary or secondary
actors. Additionally, presence or absence of AIDA components was factored into
persuasiveness, as was number of risks and benefits (shown to affect
persuasiveness in a 2007 study by Davis) and percent of time spent presenting
risks. The resulting formula was used to determine persuasiveness
Persuasiveness = Source credibility + number of AIDA components risks/benefits – (seconds spent on risks/ time of ad in seconds)
Although this formula does not give equal weight to all components, it
does take all components into consideration. Furthermore, the formula is not
being used to predict persuasiveness but rather as a comparison across
advertisements.
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Chapter Four: Study One Results
Advertisement Elements
The search of broadcast channels (ABC, NBC, CBS, FOX, and CW) for
the calendar year 2010 yielded 8,231 mentions of the prescription drugs under
consideration on television programs; of these, a random number generator
selected a ten percent sample. Most times, the drug mentions selected
appeared in an advertisement, although occasionally the hit was a mention on a
television program or news story (this problem was most evident with Viagra). In
such cases, the next hit that was an advertisement was sampled. This search of
823 occurrences resulted in 51 unique advertisements across the 15 drugs
examined. Lipitor and Lyrica had the highest number of unique ads with five
each; in contrast, the random draw only returned one Celebrex ad airing during
2010. These 51 advertisements were used for the analysis.
Advertisements ranged in length from 29 seconds to 90 seconds, with a
mean time of 62.02 seconds. The most common advertisement length was 60
seconds (28 advertisements), with 33 advertisements lasting between 54 and 61
seconds. Seroquel ads had the longest average run time with 90 seconds for two
ads, while Nasonex had the shortest advertisements at 29 and 30 seconds,
respectively.
Advertisements presented an average of 17.49 risks (16.06 in voice track,
2.71 in text) and 4.59 benefits (4.14 in voice track, 2.41 in text); however, the
“voice track” and “in text” categories were not mutually exclusive, as it was
common for a risk or benefit to be mentioned both in the voice track and in on-
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screen text. All advertisements contained both risks and benefits, except those
for Viagra, which named no specific benefits. For all drugs but Viagra, a risk-tobenefit ratio was calculated; values ranged from 0.67 (Nasonex) to 35 (Cymbalta)
with a mean of 6.67. Cymbalta was found to be an outlier, and when excluded
from the data, risk-to-benefit ratios ranged from 0.67 to 11.77 (Lunesta) with a
mean of 4.03. Because both Cymbalta and Viagra were outliers in terms of
mention of benefits, they were excluded from the persuasiveness composite
analysis. However, the advertisements for these drugs were still kept in analyses
for all descriptive variables and only excluded from those tests which involved a
persuasiveness or risk-to-benefit score. Persuasiveness composite scores
ranged from -27.6 to 7.73, with a mean score of 1.38.
Actor Characteristics
The average number of actors per advertisement was 3.78, with 0.90
primary, 0.96 secondary, and 1.88 background actors. Cymbalta ads had the
highest mean number of actors with 9.75, but these ads did not contain any
primary actors; instead, they had several actors with equal prominence, all of
whom were coded as “secondary.” Following Cymbalta, Aricept had an average
of 6.5 actors per advertisement while also having a primary actor. Plavix,
Nasonex, Nexium, and Lipitor all had the lowest average number of actors per ad
(n= 2). Altogether, the 51 advertisements contained 193 actors (46 primary, 49
secondary, and 93 background).
Of the actors who had all source characteristics coded, most were
trustworthy (72.5%), likeable (90.2%), sociable (86.3%), and attitudinally (90.2%)
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and demographically (90.2%) similar. (Attitude and demographics of target
audience were defined by the typical group to use the drug; for example, Viagra
had a target audience of men over 50 as determined by both coders.) No actors
were considered untrustworthy or unlikeable; rather, in some cases, these
characteristics were unclear (missing percentages). Most actors also had
experience taking the drug (74.5%), and they usually were not celebrities (96.1%;
the only celebrity in sample was Antonio Banderas in two Nasonex ads). The
average actor composite score, which considers all characteristics and calculates
a possible value between 0 to 8, for all advertisements was 5.41.
Use of Text
The first content analysis hypothesis, which suggested that more benefits
would be presented in advertisement text, was not confirmed. On average, 2.71
(SD= 3.21) risks were presented in text in comparison to 2.41 benefits (SD=
2.51). Although this difference was significant (t(50)= 7.55; p < .01, it was in the
opposite direction expected.
Regarding text congruency and CA RQ1, significant mean differences
were found between presentation of risks and presentation of benefits (p < .01).
With risk information, only 13.31% of voice track information was presented in
text; conversely, 46.1% of voice track benefit information was present in text. So,
even though advertisement text contained more risk information than benefit
information, there was greater consistency in text with benefits, possibly
suggesting a greater emphasis on benefits through repetition.
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To answer CA RQ2, only text congruency for risks was significantly
related to advertisement persuasiveness (Pearson’s r = -0.664; p < .01). Thus,
advertisements were more persuasive when text congruency (i.e., information in
both voice track and on-screen text) for risk information was low. This association
was not true for benefit text congruency.
Pace, Timing, and Type of Voice Track
Content analysis hypothesis two, which suggested that risks would be
presented more quickly than benefits, was confirmed in the expected direction.
Advertisements presented risks at an average rate of 0.64 risks per second;
benefits were presented at a rate of 0.34 risks per second. This difference was
statistically significant (t(50)= 15.18 ; p < .01). Because this variable was
considered when creating the persuasiveness composite score, we did not
compare voice track rate to persuasion.
Regarding hypothesis three, benefits were presented before risks in all 47
advertisements containing both risks and benefits. Thus, this hypothesis was
confirmed in the expected direction. There was no variability in order, so no
comparison to ad persuasiveness was appropriate. Additionally, 21 of the 47
advertisements presented benefits both before and after risks. Although no
significant differences in persuasiveness were seen between ads presenting
benefits in one or two segments, this finding still relates to potential primacyrecency effects (Miller & Campbell, 1959), which may influence ad recall.
Most advertisements (82.4%) used the same voice for both risks and
benefits. Primary narrators (i.e., people who do not appear on camera) were
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more likely to be male (60.2%). Advertisements using a male narrator instead of
a female were significantly more persuasive (t(50)= 40.53; p < .01), but there
were no significant differences in persuasiveness between the ads that had
different voices for risks and benefits and those that did not. These findings
address CA RQ3.
Image Congruency
Images were more likely to be incongruent during presentation of risks
than during presentation of benefits. As previously described in the methods
section, congruent, neutral, and incongruent images received scores of 1, 0, and
-1, respectively. Thus, any mean score below zero represents image
incongruency while any score above zero represents image congruency. Overall,
a significant (t(50)= 4.54 ; p < .01) difference existed between mean image
congruency for risks (-0.71) and benefits (0.45). Because the mean image
congruency score for risks was below zero and the mean image congruency
score for benefits was above zero, we can confirm CA H4. Risk information is
likely to be presented with incongruent images, while benefit information is likely
to be presented with neutral or congruent images. However, neither image
congruency score was significantly related to advertisement persuasiveness.
Thus, CA H5 cannot be confirmed.
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Chapter Five: Study One Discussion
Although the main variables examined in this study, images and
persuasiveness, were not found to be related, the study still produced several
findings of interests. Three of the five content analysis hypotheses (risks
presented faster, benefits before risks, images incongruent for risks) were
confirmed, and tests of another hypothesis (more benefits than risks in text)
showed significant findings in a direction opposite from the one expected.
Altogether, these findings show that risks and benefits are indeed presented
differently in DTC advertisements.
Congruency and Persuasiveness
Findings about text congruency suggest that even though advertisement
text contains more risks than benefits, more repetition exists with benefits; in
turn, consumers have a greater chance of receiving and internalizing this
information over risks. However, all text was coded the same way, and it is
possible that coding for text size may change these results. A future study may
want to consider text prominence in the advertisement and weight text
congruency accordingly. As expected, risks in the voice track were presented
more quickly than benefits.
Interestingly, ad persuasiveness differed depending on gender of voice
track narrator, with advertisements narrated by males considered to be more
persuasive. Relative uniformity existed with regard to advertisement structure
(benefits before risks); although this finding aligned with CA H3, insufficient
variability existed to examine differences in persuasiveness.
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Findings on image congruency confirmed those by Baird-Harris (2009),
who showed that images during presentation of risks tended to be inconsistent
with voice track, while images shown during presentation of benefits tended to be
consistent. When examined in conjunction with the findings on presentation of
risks and benefits, it is possible that image congruency may play a role in
processing according to models like the ELM (Petty & Cacioppo, 1986). Ability to
comprehend risks may be compromised due to a fast presentation in voice track
and lack of repetition in text, so people may be more likely to rely on peripheral
cues like images.
Limitations and Future Implications
Testing the effects of these incongruent images on recall and
comprehension of risks and benefits has yet to be done; thus, a clear avenue
exists for further study. First, study one served as an introduction to a second
study. In the second study, advertisements were manipulated to contain either
incongruent or neutral imagery during presentation of risks and participants will
be tested on recall of risks and benefits and asked about perceived
persuasiveness of the advertisements. The findings from study two hopefully
provide another, more standardized way of assessing persuasiveness than this
content analysis, since persuasiveness coding was fairly simple and only used
two researchers.
Both this analysis and study two can help to determine whether DTC
advertisers are satisfying criteria of fair balance. The findings from this content
analysis indeed show that risks and benefits are presented differently, despite
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the regulations stating they must be given equal prominence. The future study
will take these findings one step further.
Even though this study has the potential to provide new insight into DTC
prescription drug advertising, it is not without potential limitations. First, coding for
presence or absence of persuasiveness characteristics may be too simplistic;
persuasion in advertising likely falls along a continuum. Regarding source
characteristics, the variable of attractiveness, although possibly influential in
advertisement persuasiveness, was excluded because the two coders (one male,
one female) failed to achieve reliability in early coding stages. Additionally, using
only two coders to evaluate persuasiveness may be insufficient to draw
significant conclusions—future studies should examine ad persuasiveness with a
larger sample size. But, because this study is the first of its kind, we can draw
inferences from its findings about persuasiveness.
Regarding imagery, this study is simultaneously more sophisticated and
more simplistic than others. Baird-Harris’s (2009) study, for example, separately
coded for each second of an advertisement with regard to imagery. In contrast,
imagery in this study was only coded for two segments of the advertisement—
once during benefit presentation and again during risk presentation. The
approach to this content analysis, although related to Baird-Harris’s, significantly
differs from other studies. Adding persuasiveness brought several variables into
the coding protocol, particularly with source characteristics. Arguably,
persuasion is a product of the entire advertisement and cannot be measured for
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each individual second. For this reason, this study looked at the advertisements
holistically using Strong’s (1925) AIDA components.
Although this study is somewhat exploratory, its coding protocol is
innovative. Few studies outside of Baird-Harris (2009) have looked at
incongruent imagery in televised DTC advertisements, and none have added
persuasiveness elements to the equation. For this reason, this study is not only
contributory to the field of communication, but opens doors for future research as
well.
Should this analysis and study two show fair balance criteria to be largely
unsatisfied, health literacy concerns may arise. Without proper portrayal of risks
and benefits, patients may be unable to evaluate whether certain medications are
right for them. As such, potential revisions to fair balance regulations and
adaptations of ads for lower health-literate populations may be necessary.
Because of the importance DTC advertising has for prescription drug decision
making (see e.g., AARP, 2010), satisfying fair balance becomes not only a legal
concern, but also a safety and ethical one. If advertisers are not following these
guidelines, then consumers may be on the wrong decision-making path before
they step inside a physician’s office. Deconstructing these advertisements, then,
not only contributes to the study of communication but also addresses a potential
public health concern as well.
Logically, looking at the effects of different types of DTC advertising is the
next step. This content analysis ensured that the advertisements chosen for the
next phase of this study did contain incongruent imagery during presentation of
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risks. Additionally, examining the persuasiveness elements (e.g., source
characteristics, AIDA components) across advertisements attempted to control
for some factors that could influence information processing. In this way, this
content analysis provided the foundation for the larger experiment, study two.
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Chapter Six: Study Two Methods
Before experimenting with advertisement manipulation, a small pilot study
was necessary. This study was run to gather information about the conditions
treated by the drugs. These results were used to determine which drugs were
both most relevant and least stigmatized for the population of undergraduate
students, the sample for study two. Advertisements for drugs satisfying these
criteria were coded for perceived persuasiveness and image congruency. This
analysis led to final selection of advertisements for the experiment; ads left in
their original (i.e., image incongruent) form were shown to a control group, and
ads manipulated to contain neutral imagery were shown to an experimental
group. Differences in recall and perceived ad persuasiveness were examined.
Participants and Recruiting
Participants were 387 undergraduates at the University of Kentucky. They
were recruited through UK’s SONA system (online subject recruitment) and
received partial course credit for their participation in this IRB approved study.
Participants ranged in age from 18-51 (M= 20.06; SD= 3.573), and were primarily
White (n= 323; 85.3%), followed by African-American (n=36; 9.6%). Two hundred
nineteen (56.6%) of the participants were female.
Although differences in comprehension of drug risks and image
congruency may be most extreme among populations with low health literacy,
starting with a relatively well-educated population may control for some variation
in literacy and health literacy. Additionally, because risk information contains
complex language, college students should be best equipped to understand the
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majority of risk information. According to Kaphingst and DeJong (2004), collegelevel reading ability is necessary to comprehend the average brief summary. If
college students can understand the risk information when it stands alone (or, at
least have similar levels of ability to do so), then this study can somewhat isolate
image congruency as an independent variable relating to risk information
comprehension.
In addition, because of their high education level, college students are
likely able to critically evaluate advertisement information better than the general
public. Using this demographic to compare image congruency, then, makes
sense, as analytical skills are likely to be somewhat equal between the
comparison groups.
Advertisement Selection
As previously mentioned, advertisements were selected based study one
and the pilot study looking at condition stigma and relevance. The stigma and
relevance study helped to choose appropriate drugs and conditions for the
college-aged sample, and the content analysis helped to choose which
advertisements were used for the chosen drugs.
Stigma and relevance study. In order to control for attention,
advertisements selected must be relevant to college students. Additionally, it is
important to eliminate drug advertisements for any potentially stigmatizing
conditions (see Davis, 2007) because the sample may be unwilling to associate
themselves with the condition and thus “tune out” the advertisement.
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To determine drug relevance and stigmatization, a small pilot study was
run with a convenience sample of 42 undergraduates. Students rated the health
conditions in the drug sample, which included the following: depression, asthma
(also used as a proxy for other breathing conditions), high cholesterol,
schizophrenia, insomnia, fibromyalgia, seasonal allergies, acid reflux, and
erectile dysfunction. Each condition was rated on two bipolar, six-point semantic
differential items (no stigma to very strong stigma; not relevant to very relevant)
(See Appendix E). Then, the mean for condition stigma was subtracted from the
mean for condition relevance. This formula combined stigma and relevance to
determine conditions best suited for a study with the undergraduate population.
Based on these conditions, the three most appropriate conditions were
asthma, insomnia, and seasonal allergies. Insomnia and allergies each only had
one drug in the sample, Lunesta and Nasonex, respectively. However, multiple
drugs in the sample treated asthma, COPD, or other breathing problems. Advair
was selected because it was the most often prescribed drug for that condition
(fourth most prescribed overall in 2010).
Content analysis. Study One (described in detail in Chapters Two
through Five) helped identify the individual advertisements for each drug (three
total; one for each drug). Because multiple advertisements aired for each drug,
decisions needed to be made about which ad to include. Together, the three
drugs had nine unique advertisements out of the sample of 51 (Advair 4, Lunesta
3, Nasonex 2). We chose the ad with the highest persuasiveness score in an
attempt to control for persuasiveness across messages.
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Persuasiveness scores ranged from 14.28 to 15.87 for Advair, 7.25 to
10.85 for Lunesta, and 13.81 to 14.80 for Nasonex (higher scores represent
more persuasive advertisements; see Appendices G and H). Ideally, the
composite scores for the three ads selected would match; however, it is difficult
to compare advertisements between drugs. Actors in the Lunesta ads, for
example, lacked dynamism and sociability because they were sleeping, which
caused lower source credibility scores. Additionally, the Nasonex ads had a
bumblebee voiced by Antonio Banderas, who was the only celebrity present in
the sample; although the bumblebee got additional credibility because of
celebrity status, it scored low in the similarity categories. Thus, the best use of
the composite scores was to identify the most persuasive advertisement for each
drug, since the study’s focus is to compare differences within the same ads (e.g.,
incongruent-image Advair versus neutral-image Advair) and not across different
ads (e.g., incongruent-image Advair versus incongruent-image Nasonex).
Indeed, having some diversity across advertisements increases the
generalizability of this study’s findings because advertisement elements are
unlikely to be consistent across brands and drugs.
Also, all ads contained congruent imagery during presentation of benefits,
but incongruent imagery during presentation of risks. In this way, the
advertisements satisfied criteria set by Baird-Harris (2009).
Message Manipulation
Because the original advertisements selected contained incongruent
imagery during the presentation of risks, they were defined as the comparison
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condition. For the experimental condition, images during the presentation of risks
were removed and replaced with a neutral image of the drug name taken from
another frame in the advertisement (to control for quality and consistency). Study
of images congruent with risk information was not pursued for several reasons.
First, filming new congruent images would be too difficult and impractical; it
would likely create discontinuity in the advertisements because actors and setting
would be impossible to replicate exactly. Additionally, creating congruency
between presentation of risks and images depicting side effects would probably
decrease message persuasiveness; for example, a pharmaceutical company
would likely not agree to show an image of someone experiencing a stroke, even
if that was an increased risk of taking the drug. For this reason, incongruent
images were replaced with neutral, rather than so-called “congruent” ones.
No message checks for image congruency were necessary because the
content analysis portion of the study had already determined the ads to contain
incongruent images during the presentation of risks. As O’Keefe (2003) argued,
message checks are unnecessary when manipulating intrinsic properties of a
message; regardless of participants’ perceptions, the images from the neutral
and incongruent conditions differed. The message check cannot check the
adequacy of the manipulation—either images are the same or they are not.
Also, conducting a message check with the sample (i.e., asking when
risks are presented and if images were incongruent during that time) would have
been difficult because participants would have to remember specific side effect
information in order to participate. Additionally, a message check on image
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congruency would have drawn attention to the variable of interest and possibly
decreased validity.
Procedure
This study took place in a lab with students watching the advertisements
and completing all survey measures on computers. In an effort to create a natural
viewing environment, the advertisements were embedded during natural
commercial breaks in a ten-minute segment of ABC’s Modern Family. This show
was chosen because for the 2010-2011 season, Modern Family was the toprated scripted show on broadcast television (sixth overall behind sports, news
programs, and reality shows) among the 18-49 demographic and averaged
approximately 6.4 million viewers per week (Gorman, 2011). Of shows recorded
on DVR, Modern Family also ranked first in 2010-2011. Because 2010
encompassed both the 2009-2010 and 2010-2011 viewing seasons, figures for
the 2009-2010 season were also gathered. Although the series was in its first
season, it still ranked 21st overall and was the sixth most popular situation
comedy (Andreeva, 2010). A ten-minute segment was chosen for practical
reasons; including a full half-hour episode of the show would not only have
contributed to long study time but also would have contributed to potential
participant fatigue. (A 2007 study by Helme, Donohew, Baier, and Zittleman used
similar logic.)
In addition to watching the DTC ads, participants also watched original
commercials from the selected broadcast. The original advertisements were
included in an attempt to increase ecological validity. The ten-minute segment
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was broken in half by a commercial break containing five commercials (DTC ad,
original ad, original ad, original ad, same DTC ad), resulting in total viewing time
of around 13 minutes.
Before watching the advertisements, participants were asked for
demographic information and general knowledge of prescription drugs (see
Appendix I). In an attempt to control for the motivation element of ELM’s central
processing route, participants were told to pay close attention to the drug
advertisements and that they would be tested following the completion of
program and commercial viewing. Controlling for motivation attempted to negate
any potential priming effects from the drug knowledge scale.
Participants were randomly assigned to a condition of either risk-image
incongruency (comparison, using unmodified advertisements) or risk-image
neutrality (experimental, using modified advertisements) for each of the three
drugs, creating six conditions (original Advair, modified Advair, original Lunesta,
modified Lunesta, original Nasonex, modified Nasonex).
Immediately after watching the program and commercials, students were
asked to complete a computerized post-test survey measuring recall of risks and
benefits and message persuasiveness (see Appendix J). All experimental
protocols and instruments were approved by the IRB at the University of
Kentucky before study administration.
Experiment Measures
Baseline. As previously mentioned, participants completed a short survey
before viewing the advertisements and program. Basic demographic information
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such as age, gender, and race/ethnicity was collected to gain insight about the
sample. Cacioppo, Petty, and Kao’s (1984) 18-item short-version of the “Need for
Cognition” scale was also given, as well as a measure for knowledge of product
class adapted from Lichtenstein, Netermeyer, and Burton (1990). The
Lichtenstein et al. measure included four items using seven-point Likert-type
scales (strongly disagree-strongly agree; not very knowledgeable- very
knowledgeable); one example of an adapted item was “I have a clear idea about
which drug characteristics are really important ones in providing me with
maximum usage satisfaction” (strongly disagree- strongly agree). (The entire
baseline measure is available in Appendix I.)
Post-test. After viewing the advertisements and program, participants
were surveyed on benefit and risk recall, general perceptions of product
knowledge, and overall advertisement perceived persuasiveness.
Recall of risks and benefits was cued and based off of measures
developed by Cameron (1994), who asked participants whether specific phrases
occurred in a print advertisement or story. Although Cameron’s measures were
used with print, the logic can also extend to broadcast advertisements. To keep
the focus on congruent or incongruent imagery, the phrases used in the
questions did not appear in superscript or subscript text. For Advair and Lunesta,
whose advertisements were roughly 60 seconds long, two questions for risks and
two questions for benefits were asked. Because Nasonex’s advertisements were
only 30 seconds long, only one question each was asked for risks and benefits.
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Prior to answering risk and benefit questions, participants were asked to identify
drug name and health condition from the advertisements.
Although free recall may have been a more appropriate measure of recall
of risks and benefits, multiple choice questions (like the 1994 Cameron study)
were used because of the number of participants. Coding 387 participant
responses would have been tedious; also, because multiple benefits and risks
(sometimes as high as 20) were presented, we did not expect participants to
remember all of the information mentioned in the advertisements. Correct
answers to multiple choice questions, then, were used as a proxy for recall.
Measures of perceived product knowledge were adapted from Smith and
Park (1992); the scale contained four items (e.g., “If I had to ask my doctor for
this drug today, I would need to gather very little information in order to make a
wise decision.”) on a seven-point Likert-type scale (strongly disagree to strongly
agree).
Brand interest was adapted from Machliet, Allen, and Madden (1993), who
used four items (e.g., “I’m a little curious about [drug name].”) on a seven-point
Likert-type scale (strongly disagree to strongly agree). Brand interest can serve
as a proxy for purchase intention in this study because, as previously mentioned,
our participants do not have the ability to prescribe medication. Instead, the
action step in the advertisements tells people to ask their doctor about a drug;
thus, the advertisement’s purpose is to stimulate brand interest.
However, having a more direct measure of “purchase intention” is
necessary it is a clearer indicator of the effectiveness of the message’s action
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step. For this reason, two items were selected from a purchase intention scale
developed by Dodds, Monroe, and Grewal (1991) and adapted for prescription
drugs by changing the phrase “purchasing” to “asking for”: “If I was suffering from
[condition], the likelihood of me asking for [drug name] is…” and “If I was
suffering from [condition], my willingness to take [drug name] is…” Both items
were scored on a seven-point Likert-type scale (very low to very high). (The
entire post-test instrument is available in Appendix J.)
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Chapter Seven: Study Two Results
Sample Demographics
As previously mentioned, the experiment’s sample consisted of 387
undergraduate students, most of whom were female (n= 219; 56.6%) and White
(n=323; 85.3%). Participants ranged in age from 18-51 with an average age of
20.06 (SD= 3.57); 95.1% of the sample was age 25 or younger. After data
cleaning, distribution among the three drugs was relatively even, with 128
participants viewing advertisements for Advair (64 original; 64 modified), 129
participants viewing advertisements for Lunesta (64 original; 65 modified), and
130 participants viewing advertisements for Nasonex (64 original; 66 modified).
No significant differences in gender, race, or age existed between the six
conditions.
In general, participants exhibited a relatively high need for cognition (M=
59.56; SD= 10.59; range= 22-85); the possible range was 18 to 90 with higher
scores representing a greater need for cognition. Males were shown to have a
higher need for cognition (M= 61.71; SD= 9.58) than females (M= 57.90; SD=
11.05); this difference was significant (F (1, 385)= 3.91; p< .05).
Participants also had a low-to-medium familiarity with the drug in their
given advertisement (M= 1.28 on scale of 1-3; SD=.60), as 304 participants
(78.8%) had never taken the drug and did not know anyone who had, whereas
13.7% (n= 53) knew a friend or family member who had taken the drug and the
7.5% (n=29) currently were taking or had taken the drug in the past. Most
participants did not experience any symptoms (n=246; 63.6%) or did not
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experience symptoms severe enough to take medication (n= 108; 27.9%) for the
condition treated by the drug in their condition (M= 1.46 on scale of 1-4; SD=.67).
No significant differences in need for cognition, familiarity, or symptom
experiences existed between the six conditions.
Most participants (n= 384; 99.2%) were able to recall the drug shown in
the advertisements and the condition for which that drug treats (n=381; 98.4%).
There was little variation across drug and congruency condition.
Data regarding hypotheses were analyzed through various methods,
including t-tests and ANOVAs. The experiment had a 3 x 2 design (three drugs;
two congruency conditions), creating six overall groups.
Benefit and Risk Recall
Hypothesis 1 Not confirmed
Findings regarding recall of risks and benefits were inconclusive. Overall,
participants recalled an average of .92 benefits and .88 risks; therefore there
were no significant differences in recall of risks and benefits (F(1, 385)= .70, p=
.41) between congruency conditions. An analysis of variance showed that no
significant differences existed between recall of risks and benefits with respect to
Advair; however, significant differences did exist with Lunesta and Nasonex.
These differences, though, were in opposite directions than the expected
hypotheses. (See Appendix J for the answers to specific questions.)
Advair. On average, participants were able to provide .88 correct answers
(of 2; SD= .72) for recall questions about benefits and .90 correct answers (of 2;
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SD=.80) for risks. There were no significant differences in recall for this drug
(F(1,126)= .03; p= .86).
Lunesta. Those participants who saw advertisements for Lunesta were
able to provide an average of 1.05 correct answers (of 2; SD=.25) for recall
questions about benefits and 1.32 (of 2; SD=.64) for risks. This difference was
significant (F(1,127)= 19.76; p< .01); however, it was in the opposite direction of
the expected hypothesis.
Nasonex. Participants who saw advertisements for Nasonex were able to
recall an average of .83 (of 1; SD=.38) benefits in multiple choice questions, but
only .38 (of 1; SD=.49) risks. This difference was significant (F (1,128)= 81.81;
p< .01) and in the direction expected.
Even though findings regarding Nasonex supported Hypothesis 1, the
hypothesis was not confirmed for Advair or Lunesta. These findings suggest that
differences exist with individual messages that influence recall of benefits versus
risks.
Risk Recall and Image Congruency
Hypothesis 2 Not confirmed
Overall, an analysis of variance showed that participants recalled an
average of .84 (of 2; SD=.05) risks in the incongruent (i.e., original) condition and
.89 (of 2; SD=.05) risks in the neutral (i.e., modified) condition. This difference
were not significant (F(2, 384)= .69; p=.41)
Advair. A one-tailed independent sample t-test revealed no statistically
significant differences (t(127)= 1.57 ; p=.06) in risk recall for the two conditions.
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In the incongruent condition, participants recalled an average of .87 (of 2;
SD=.83) risks whereas participants in the neutral condition recalled .96 (of 2;
SD= .77) risks.
Lunesta. Similarly, a one-tailed independent sample t-test showed no
significant differences existed in risk recall for the two Lunesta conditions
(t(128)=.09; p=.47). Participants recalled an average of 1.29 (of 2; SD=.63) risks
in the incongruent condition and 1.35 (of 2; SD=.65) risks in the neutral condition.
Nasonex. In both Nasonex conditions, participants recalled .38 (of 1; both
SD= .49) risks; thus, no difference existed in recall depending on image
condition.
Other covariates. Despite the lack of significant differences by
congruency condition, two covariates were found to be significant.
Need for cognition. Not surprisingly, need for cognition was shown to
covary with number of correct risks recognized (F (1, 385)= 5.28; p < .05; Ƞp 2 =
.01). This finding is expected, as people with high need for cognition may be
more likely to pay attention to the advertisements and thus internalize and recall
more risks, regardless of image congruency condition.
Drug advertisement. Type of drug advertisement (i.e., Advair, Lunesta,
or Nasonex) was also shown to covary with correct risks recalled (F (2, 384)=
55.38; p <.01, Ƞp 2 = .23). This finding points to a difference in advertisements
selected; however, it may also be the result of the fact that the Nasonex post-test
assessment only asked participants to recall one risk, while Lunesta and Advair
asked questions about two risks.
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Interactions. A three-way interaction was found between drug,
congruency condition, and gender (F(1, 385)= 3.30; p <.05, Ƞp 2 = .02). No other
significant interactions were found.
Gender and Advair. As expected, subjects were less likely to recall risks
in the incongruent (M= .67 of 2; SD=.11) than neutral (M= .97 of 2; SD= .120)
conditions, but this finding only applied to females; this difference was statistically
significant (t(64)=3.36; p <.01; Ƞ2= .15). This finding is in line with the rationale
behind H2.
However, males were actually more likely to recall risks in the incongruent
(M= 1.08 of 2; SD= .12) than neutral (M= .95 of 2; SD= .11) conditions; this
difference, though, was not statistically significant with a one-tailed t-test (t
(62)=1.579; p= .06).
Gender and Lunesta. Similar to the Advair results, females were less
likely to recall risks in the incongruent (M= 1.21 of 2; SD= .11) than neutral (M=
1.45 of 2, SD= .11) image conditions (t(71)=2.90, p <.01, Ƞ2=.11). In contrast,
males produced the opposite results (incongruent M= 1.36 of 2; SD= .13; neutral
M= 1.20 of 2; SD= .12), but this difference was not statistically significant
(t(55)=1.60, p=.06).
Gender and Nasonex. Nasonex differed from Advair and Lunesta in that
differences in recall females and males were in the opposite directions. With
Nasonex, females had worse recall (M= .34 of 1; SD= .11) in the neutral
condition than in the incongruent condition (M= .45 of 1; SD= .10) although this
difference was insignificant. Unlike with Advair and Lunesta, men had worse
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recall in the incongruent (M= .28 of 1; SD= .13) to the neutral (M= .48 of 1; SD=
.13), and this difference was statistically significant (t(49)= 2.094; p <.05;
Ƞ2=.08).
Persuasiveness and Image Congruency
Hypothesis 3 Not confirmed
No significant results were found regarding persuasiveness (brand interest
and “purchase” intention) or advertisement knowledge, but some results were in
the expected direction.
Perceived product knowledge. Results show that the mean knowledge
score (scale of 1 to 7; higher scores represent greater knowledge) was higher in
the neutral groups (M= 3.50; SD= 1.17) than the incongruent groups (M= 3.40;
SD= 1.32), although these differences were insignificant. For Advair, participants
had an average score of 2.90 (SD= 1.35) in the incongruent condition but 3.03
(SD= 1.06) in the neutral condition. For Lunesta, participants also had scores of
3.44 (SD= 1.11) in the incongruent condition but 3.55 (SD= 1.06) in the neutral
condition. Finally, for Nasonex participants rated knowledge at 3.86 (SD= 1.32),
for the incongruent condition and 3.89 (SD= 1.22) for the neutral condition. Thus,
knowledge scores were higher for all drugs in the neutral condition but these
differences were not significant.
Product knowledge and drug. ANOVAs revealed that ad knowledge in
post-test did differ depending on drug (F(2, 384)= 20.45; p < .01, Ƞp 2 = .10),
again suggesting that differences existed among the messages in the
advertisements.
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Brand interest. As expected, means for brand interest were higher for the
incongruent groups (M= 3.50; SD= 1.31) than the neutral groups (M= 3.38; SD=
1.27); however, we cannot conclude that incongruent advertisements were more
persuasive in this regard because overall these differences were not significant
(t(385)= .74; p = .39). This pattern did hold true, though, for Advair (incongruent
M= 3.42, SD= 1.44; neutral M= 3.12, SD= 1.26) and Nasonex (incongruent M=
3.58, SD= 1.26; neutral M = 3.52, SD= 1.27), although this difference was only
statistically significant for Advair (t(125)= 4.19; p <.01; Ƞ2 =.12; Nasonex t(128)=
.85; p= .20). Lunesta, however, did not display this pattern (incongruent M =
3.46, SD= 1.24; neutral M= 3.49, SD= 1.25) but their means were not statistically
different (t(126)= -.42; p= .66).
Brand interest and product class knowledge. Knowledge of product
class (scale of 1 to 7; higher scores represent greater product knowledge;
adapted from Lichtenstein, Netermeyer, & Burton (1990)) had a significant
relationship with brand interest (F(1, 385)= 7.82; p < .01; Ƞp 2 =.02). Perhaps
those who are interested in prescription drugs in general pay more attention to
advertisements and thus gain greater knowledge on product class.
Purchase intention. Results regarding likelihood of asking a doctor about
a drug, referred to as “purchase intention” (scale of 1 to 7; higher score means
more likely to ask a doctor about drug) showed that means were slightly lower for
the neutral groups (M= 4.19, SD= 1.50) than the incongruent groups (M= 4.26;
SD= 1.36); although in the expected direction, these means were not significantly
different (t(385)= .484; p= .487). This pattern was true for Lunesta (incongruent
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M= 4.27, SD= 1.45; neutral M= 3.98, SD= 1.64) and Nasonex (incongruent
M=4.27, SD= 1.31; neutral M= 4.05, SD= 1.55) but not Advair (incongruent M=
4.24, SD= 1.35; neutral M= 4.54, SD= 1.22). All of these differences were
statistically significant (Lunesta t(126)= 3.87; p < .01; Ƞ 2 =.11; Nasonex t(128)=
2.96; p <.01; Ƞ2 =.06; Advair t(125)= -3.98; p < .01; Ƞ2 = .11), although the lack of
consistency in direction makes drawing conclusions difficult.
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Chapter Eight: Discussion
Although this study’s hypotheses were not fully confirmed, results were
often in expected directions, and some interesting relationships between
variables emerged. Additionally, differences between drug advertisement
(regardless of image congruency) were shown to be significant with all three
hypotheses; these clear message differences are the main limitation of this study
and will receive further discussion. However, the study does open up a few
avenues for discussion.
Recall
Despite findings by Day (2006), no statistically significant mean
differences were found in benefit and risk recall when all drugs and conditions
were considered together. However, statistically significant differences were
shown for both Lunesta and Nasonex individually. These differences, though,
were in opposite directions: with Nasonex, participants had greater recall of
benefits, but with Lunesta, participants had greater recall of risks. According to
the content analysis (see Chapter Three), though, Lunesta gave far greater
prominence to risks in the chosen advertisement by spending 25 of 60 seconds
listing 19 risks in the voice track, whereas Nasonex spent five of 30 seconds
listing five risks (these drugs were at polar ends of the risk-to-benefit range in the
content analysis results; see p.26) Additionally, some of the side effects of
Lunesta (e.g., hallucinations, fatal throat swelling) are more severe than those of
Nasonex (e.g., sore throat, headache). Thus, Lunesta’s longer list of severe side
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effects and longer time spent on risks may have caught the viewer’s attention
more than Nasonex’s shorter, less severe list of risks.
In addition to the differences in risks, Nasonex lists more concrete benefits
in both voice track on on-screen text, such as relieving congestion, runny nose,
and sneezing. Conversely, Lunesta lists benefits that are vaguer: “get the restful
sleep you need” and that it “keys into receptors that support sleep, setting [a
person’s] sleep process in motion”. The idea of “receptors” may also be
unfamiliar to viewers, which could impact recall after viewing the advertisement.
Regarding H2, which addressed the effect of image incongruency, means
in risk recall were higher (or the same, as in the case of Nasonex) for those
participants viewing neutral advertisements than those viewing incongruent ones;
however, these differences were not significant, so no conclusions can be drawn.
But, a few relationships were found regarding drug advertised, need for
cognition, and gender.
Like with H1, significant differences were shown in risk recall across the
three drugs. However, this finding may be relatively meaningless, as participants
were only asked to recall one risk with Nasonex, but two with Advair and
Lunesta. Thus, because it was impossible for the number of risks recalled to go
above 1 in the Nasonex groups, it is difficult to make generalizations across
drugs.
A three-way interaction was shown between drug, congruency condition,
and gender, suggesting that gender plays a role in recalling risks and benefits.
Females were significantly better in recall when presented with neutral images
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with Advair and Lunesta. Although means suggested that females viewing the
neutral Nasonex advertisement had worse recall, the difference was not
statistically significant. So, we can conclude that females are better in recalling
risks when incongruent images are eliminated, at least for two of the three drugs.
As previously mentioned, the Nasonex advertisement was considerably shorter
both in advertisement length and time spent on risks, so perhaps these other
factors affected recall.
Men, however, showed almost the reverse pattern: means in risk recall
were higher for the incongruent conditions than the neutral conditions for Advair
and Lunesta, but the differences were not significant. For Nasonex, though,
means were significantly higher when the inconsistent imagery was removed. So,
the hypothesis held true for that drug.
The findings for H2, then, because they were not consistent or significant
across all groups, can be considered inconclusive. However, for the gender-drugcongruency conditions that did have significant results, mean differences were in
the expected direction and supported H2.
Perhaps some of the receiver-based differences in gender and risk recall
dealt with the genders of the actors used in the advertisements. For Advair, the
content analysis (see Chapter Three) determined that the primary actor in the
advertisement was a White elderly (defined as over 65) male and the narrator
was also male. Conversely, with Lunesta, both the primary and secondary actors
were female, and the advertisement used a female voiceover. Advair chose to
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use males while Lunesta used females, yet both showed an increase in recall for
females in the neutral conditions, but not males.
The content analysis showed Nasonex differed from Lunesta and Advair in
three ways: (1) it contained main actors of both genders; (2) it contained an
animated character (the bumblebee); and (3) the bumblebee had a celebrity
voice (Antonio Banderas; although he may not have been recognized, the name
was clearly male). Perhaps these differences can explain why results for
Nasonex were reversed from Advair and Lunesta (men had greater recall with
neutral ads; females had worse recall but the difference was not significant).
Additionally, the celebrity involved was male; a female celebrity may have
produced the opposite result, based on the content analysis’s finding that male
voiceovers were more persuasive than those that were female.
The receiver-based differences in risk recall with gender, though, have
implications for future drug advertising. Although the advertisements used in this
study were chosen for their gender neutrality, these findings suggest that
different strategies may be necessary when targeting males and females. A
further study exploring this topic with gender-specific (e.g., Viagra) drugs may
give more insight into this area.
Persuasiveness
Persuasiveness was measured in three areas (perceived product
knowledge, brand interest, and “purchase” intention), but no overall conclusions
can be drawn from findings.
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With product knowledge, means were higher for the neutral groups than
for the incongruent groups, showing a pattern of increased recall when
incongruent images were removed. However, because these differences were
not significant, we cannot say that knowledge scores were higher when
incongruent imagery was removed. In addition, drug advertised was shown to
covary with perceived product knowledge, so lack of significant findings with
product knowledge and congruency may be due to inconsistency across
advertisements for different drugs.
As expected, the Advair advertisement with incongruent imagery was
shown to stimulate greater brand interest than the neutral imagery, suggesting
that incongruent images make advertisements more persuasive. Although this
pattern was evident in mean calculations for Nasonex, the difference was not
statistically significant. Lunesta showed an opposite, albeit non-significant
pattern, but again, this finding may be related to the greater emphasis on and
severity of risks. So, while H3 held true for Advair, it did not for the other two
groups, and thus cannot be fully confirmed.
No clear conclusions can be drawn from “purchase” intention (i.e.,
intention to ask doctor about a drug). Although means were higher for the
incongruent groups than the neutral groups (suggesting greater persuasiveness
with incongruent imagery), the differences were not significant. Differences
between drugs advertised were significant, again showing a difference in
messages, but the directions were not consistent. Drug familiarity was shown to
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covary with purchase intention; this finding is logical as people who have already
“purchased” a drug or know someone who has may be more likely to do it again.
Limitations and Future Implications
Like all research, this study has limitations. As previously mentioned, clear
message differences existed depending on drug advertised. For this reason,
generalizing results across drugs was difficult. This study’s goal, though, was to
explore potential issues with fair balance, which does apply to all DTC
prescription drugs. Although hypotheses could not be confirmed with the drugs
used, perhaps better future matching of advertisements could produce significant
findings. Advertisements for this study, though, were chosen as systematically
and carefully as possible given the research materials available.
Also, participants may have already seen the advertisements, because
even though data were collected in February and March of 2012, the
advertisements had all aired in 2010 and may be in recent memory. Even if
participants had never seen the specific advertisements used, it is likely that they
may have seen another advertisement for the drugs used in the experiment. The
baseline pretest instrument only asked about knowledge of drug class, so prior
knowledge about specific drugs was not controlled for. Creating original
broadcast advertisements (similar to a 2007 study by Davis, who did so in print)
could control for this potential problem.
Additionally, the drugs chosen for the advertisements were intentionally
gender-neutral, although findings about gender suggest that future research
should examine differences in cognitive processing for males and females. For
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this reason, another study may want to look at drugs for conditions that only
affect one gender.
Even though the instrument was based on one used by Cameron (1994),
it still had limitations. A limited number of questions about risks and benefits (two
each for Lunesta and Advair, one each for Nasonex) were asked. A greater
expansion of the instrument (i.e., adding more questions) may have produced
more significant findings, particularly because some of this study’s findings were
in the expected direction. Also, the researcher chose which risks and benefits
were included in the post-test instrument, and there is no way to know if these
risks or benefits were representative of all in the advertisement (i.e., whether one
benefit or risk is easier to remember over another). Lastly, the multiple-choice
nature of these questions used cued-recall. Free recall may be more accurate in
determining what specific risks and benefits participants remembered.
Some limitations also exist with the sample used. College students may
be more likely to have higher health literacy (based on rationale from studies
such as Kaphingst & DeJong, 2004), but their age may make them less
susceptible to health conditions that require prescription drugs as treatment. A
pilot study attempted to control for relevance, but in general, prescription drugs
as a whole may not be relevant to this age group. This issue may be most
evident in the persuasiveness findings, as college students may lack motivation
necessary to create brand interest and purchase intention.
This study has its merits in that it is the first of its kind and uses novel
methods. No studies so far have attempted to manipulate images in broadcast
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DTC advertisements to check for risks and recall. Also, even though the use of a
piecemeal instrument (for which reliability and validity information is unavailable)
can be a limitation, the testing instruments used in this study can provide a
foundation for later studies. However, the instrument used in this study has room
for expansion. The operationalization of “neutral” used could be altered as well;
for example, talking heads could be used instead of a static screenshot of drug
logo. Findings regarding gender and message differences in drugs advertised
suggest that another study should use different drugs. But, hopefully this study
can serve as a model for those wishing to continue this field of research.
At this time, no clear conclusions can be drawn regarding fair balance and
image congruency, but findings show that some sort of relationship may exist.
This study, although lacking clear significant findings, opens the door for future
research, even if it suggests that image congruency does not have as great of an
effect as expected. This area certainly calls for further exploration (possibly with
different operationalization), as DTC advertising can have clear health
implications for any countries allowing such practice.
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Appendix A
Top Drugs for 2010 by Sales
(Taken from http://www.drugs.com/top200.html)
Italicized drugs advertised on television and used in analysis
Rank Drug
Current Manufacturer
Total Sales
($000)
1
Nexium
AstraZeneca
5,276,153
Pharmaceuticals
2
Lipitor
Pfizer
5,272,576
3
Plavix
Bristol-Myers Squibb
4,675,483
Company
4
Advair
GlaxoSmithKline
3,655,206
Diskus
5
OxyContin Purdue Pharma
3,554,751
6
Abilify
Bristol-Myers Squibb
3,514,265
Company
7
Singulair
Merck & Co.
3,324,909
8
Seroquel
AstraZeneca
3,222,055
Pharmaceuticals
9
Crestor
AstraZeneca
2,922,687
Pharmaceuticals
10
Cymbalta
Eli Lilly and Company
2,638,536
11
Actos
Takeda Pharmaceuticals
2,631,930
North America
12
Lexapro
Forest Pharmaceuticals
2,483,391
13
Zyprexa
Eli Lilly and Company
2,036,092
14
Spiriva
Boehringer Ingelheim
1,593,593
Pharmaceuticals
15
Lantus
Sanofi-Aventis
1,525,697
16
Aricept
Eisai Corporation
1,522,517
17
Lyrica
Pfizer
1,478,158
18
Diovan
Novartis Corporation
1,443,539
19
Effexor XR Wyeth
1,431,042
20
Concerta
Ortho-McNeil-Janssen
1,407,962
Pharmaceuticals,
21
Levaquin
Janssen Pharmaceuticals 1,355,350
22
Celebrex
Pfizer
1,349,833
23
Diovan
Novartis Corporation
1,314,507
HCT
24
Januvia
Merck & Co.
1,294,408
25
Suboxone
Reckitt Benckiser
1,164,872
Pharmaceuticals
26
NovoLog
Novo Nordisk
1,101,447
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% change
from 2009
4.9%
-2.3%
10.2%
-1.0%
13.1%
12.7%
8.9%
2.4%
27.0%
7.6%
4.2%
4.6%
7.7%
19.3%
0.3%
13.3%
-0.1%
7.0%
-40.1%
16.9%
-0.6%
-6.9%
3.7%
13.0%
26.6%
20.6%

27
28
29
30
31
32
33
34
35

36
37
38
39
40

Viagra
Atripla
Tricor
Provigil
Zetia
Geodon
oral
Vytorin
Ambien CR
Lunesta

Lidoderm
Lantus
SoloSTAR
Vyvanse
Aciphex
Nasonex

Pfizer
Gilead Sciences
Abbott Laboratories
Cephalon
Schering-Plough
Pfizer

1,028,769
1,028,753
1,015,682
999,975
985,823
959,057

5.5%
-6.5%
-17.2%
6.7%
-4.3%
8.7%

Merck & Co.
Sanofi-Aventis
Sepracor (renamed
Sunovion
Pharmaceuticals)
Endo Pharmaceuticals
Sanofi-Aventis

953,625
951,108
948,621

-16.3%
-2.5%
17.6%

934,418
933,589

-1.1%
50.5%

Shire US
Eisai Corporation
Schering-Plough

931,421
915,796
886,446

40.9%
-8.8%
-1.9%
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Appendix B
Drug Treatment Conditions
(Taken from http://www.drugs.com/top200.html)
Drug
Condition
Nexium
Gastroesophageal reflux disease
Lipitor
High cholesterol
Plavix
Prevent blood clots (after heart attack
or stroke)
Advair Diskus
Asthma and chronic obstructive
pulmonary disease (COPD)
Abilify
Clinical depression
Singulair
Asthma and COPD
Seroquel
Schizophrenia
Crestor
High cholesterol
Cymbalta
Clinical depression
Spiriva
Asthma and COPD
Aricept
Dementia
Lyrica
Fibromyalgia
Celebrex
Arthritis
Viagra
Erectile dysfunction
Lunesta
Insomnia
Nasonex
Seasonal allergies
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Appendix C
Content Analysis Coding Definitions
Advertisement Definitions
Benefits
 Discusses drug use or effectiveness
 Advantages listed over other medications
 Testimonials (positive) from other actors or spokespeople
Risks







Negative effects associated with drug
Side effects
Contraindications (conditions that make a treatment unadvisable)
Warnings
Drug interactions
Instances when one should seek medical attention if taking the drug

Target audience
 Gender and age most likely to be affected by health condition
 Age: 18-39; 40-64; 65+; Age irrelevant
 Ex: Viagra applies to males 40-64 and 65+
Voice track
 Any words spoke during advertisement
 Includes actor testimonials and narration of risks and benefits
 DOES NOT INCLUDE: general information about condition or promotional
messages (i.e., “Lipitor is produced by Pfizer.”)
 **verified using transcripts
Primary visual
 On screen image
Superscript
 Any text superimposed on top of the image
 DOES NOT INCLUDE: drug name, name of company producing drug,
logos Superscript was any text on the screen that was superimposed on
top of the image
Subscript
 Placed on a colored bar on the bottom of the screen
 Usually presented in small text and similar to subtitles
Text Congruency
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Regarding superscript and subscript: congruent if on-screen text used
words also used in the voiceover (excluding prepositions and articles)
Measured by number of unique (in text but not voice track) benefits and
risks presented

Image Congruency
 Agreement between visual or text and voiceover
 Represent ideas expressed in the voice track
 Ex: if an advertisement discussed risks and side-effects of a drug while
showing a person being active or living symptom-free, that part of the
advertisement was coded as incongruent
 Visual with a blank or out-of-focus background with drug name and text
considered neutral
 “Talking heads” (i.e., single shot of actor talking) are neutral
 Coding protocol:
(1) congruent (i.e., positive when discussing benefits, negative
when discussing risks);
(2) neutral; or
(3) incongruent (i.e., negative when discussing benefits, positive
when discussing risks).
Persuasiveness Definitions
Risk-to-benefit ratio
 Risks divided by benefits
Source characteristics:
Role
 Primary: the character is either the main or primary speaker, or in the case
of multiple speakers the individual who spoke first, or a character with a
non-speaking role who was prominently featured in the advertisement
(e.g., a vignette of his or her daily life is portrayed)
 Secondary: the character may be a major supporting character who spoke
after primary or a just a supporting speaking role, or a non-speaking
character who is featured in the ad (e.g., a vignette of their daily life is
portrayed) but is second to a primary speaking actor
 Background: non-speaking and non-focal roles
 ** Primary and secondary actors either give testimonials or were the focal
point in a primary visual at some point during the advertisement.
Trustworthiness
 Character
 Apparent sincerity (telling truth)
 Lack of self-interest (little to gain by telling or showing others experience)
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Expertise
 Specialized training
 Extensive knowledge of disease or drug
 Ex: Doctor, pharmacist
Experience
 Have taken drug (or act as if they have)

Dynamism
 Sociable; shown interacting with others in a positive way
 “Extroverted” speaking style: fluent and rapid speech, few vocalized
pauses, and appropriate vocal emphasis
Celebrity
 Recognizable celebrity figure/voice
Likability
 Researcher’s subjective opinion
Demographic similarity
 Compared to demographics for target audience for drug
Lifestyle similarity
 Similar lifestyle portrayal (same activities as target audience)
Persuasiveness:
 Strong’s (1925) AIDA model (presence/absence)
Attention (cognitive stage activity): Introduce a (new) product or new use
of an existing product (not focus on its use features, just generates
attention or buzz for it without talking about how it works - a teaser.
Product introduction without generating comprehension or providing
specific product information).
Interest (affective stage activity): Does it explain the features of the product
and/or its use, application, benefits, and consequences (risks)?
Desire (affective stage activity): Does the ad attempt to create positive
attitudes,
disposition towards the product, desire, liking, preference?
Action (behavioral stage activity): Does the ad have a call to action, asking
person to buy the product, or ask doctor about it?*
*Because AIDA (Strong, 1925) is usually used in marketing, the action activity
generally refers to purchase. However, DTC advertising is unique in that the
target market lacks the autonomy to get the product without going through an
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intermediary. So, although the action of asking a doctor about a drug could fall
under the interest category, it was placed in the action category because it is the
closest patients can come to getting the drugs themselves.
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Appendix D
Content Analysis Coding Scheme
Drug name: _________________
Ad number: _________________
GENERAL ATTRIBUTES
Product Specific? (i.e., not reminder)
1 = Yes
2 = No
**if no, do not continue with rest of coding
Length of Ad: _______________
Target Audience
Age: 1 = young adult (18-39)
2 = middle age (40-64)
3 = older age (65+)
4 = age irrelevant
5 = unsure
Gender:
1 = Male
2 = Female
3 = Neutral
Number of different people present in ad:
Each actor coded as primary, secondary (co-principle). The following is repeated
for each primary/secondary actor. Background actors are only coded for race,
gender, and age.

Primary or Secondary Actor # (visual presenter):
Animated:
1 = Yes
2 = No
Speaking role:
1 = Yes
2 = No
Gender:
1 = Male
2 = Female
3 = Both
Race:
1 = White
2 = African American
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3 = Hispanic/ Latino
4 = Asian/Pacific Islander
5 = Other
6 = Multi-racial
Age:
1 = child (under 18)
2 = young adult (18-39)
3 = middle age (40-64)
4 = older age (65+)
5= unsure
Trustworthiness:
1 = Trustworthy
0.5 = Unsure
0 = Untrustworthy
Expertise:
1 = Expert on product/condition
0.5 = Unsure
0 = Not an expert on product/condition
Expertise:
1 = Has taken drug
0.5 = Unsure
0 = Has not taken drug
Sociability (or Dynamism):
1 = Dynamic or Charismatic Person
0.5 = Unsure
0 = Not Dynamic or Charismatic Person
Celebrity Status:
1 = Celebrity (if so, list name)
0 = Not a celebrity
Likability:
1 = Likeable
0.5 = Unsure
0 = Unlikeable
Demographic similarity (to target audience):
1 = Yes
0.5 = Unsure
0 = No
Attitude/Lifestyle similarity (to target audience):
1 = Yes
0.5 = Unsure
0 = No
(For background actors appearing (check all that apply):)
Gender:
1 = Male
2 = Female
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3 = Both
Race:
1 = White
2 = African American
3 = Hispanic/ Latino
4 = Asian/Pacific Islander
5 = Other
6 = Multi-racial
Age:
1 = child (under 18)
2 = young adult (18-39)
3 = middle age (40-64)
4 = older age (65+)
Voice-over Actor/Actress (does not visually appear):
Gender:
1 = Male
2 = Female
3 = Both
Same Voice for Risks and Benefits?
1 = Yes
0 = No
Persuasiveness of Ad:
1. Attention (cognitive stage activity): Introduce a (new) product or new
use of an existing product (not focus on its use features, just generates
attention or buzz for it without talking about how it works - a teaser. Stated
differently you can have a product introduction without generating
comprehension or providing specific product information)
1 = Yes
2 = No
2. Interest (affective stage activity): Does it explain the features of the
product and/or its use, application, benefits, and consequences (risks)
1 = Yes
2 = No
3. Desire (affective stage activity): Does the ad attempt to create positive
attitudes, disposition towards the product, desire, liking, preference
1 = Yes
2 = No
4. Action (behavioral stage activity): Does the ad have a call to action,
asking you to buy the product, asking you to ask your doctor for it (Not
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asking the doctor to explain it as that would go in comprehension but to
prescribe it)
1 = Yes
2 = No
RISK SPECIFIC
Length of Time Spent on Risks:_______________
(exact times for start and stop)
Number of Risks Presented in Voice Track:
Number of Risk Presented in Superscript/Subscript:
Unique Risks Presented in Superscript/Subscript (i.e., not in voice track)
1 = Yes
2 = No
Text Congruency: Number of unique risks presented in superscript/subscript:
_______
Image Congruency:
1 = incongruent (positive when discussing risks)
2 = neutral
3 = congruent (negative when discussing risks)
BENEFIT SPECIFIC
Length of Time Spent on Benefits:__________________
(exact time start and stop)
Number of Benefits Presented in Voice Track:
Number of Benefits Presented in Superscript/Subscript:
Unique Benefits Presented in Superscript/Subscript (i.e., not in voice track)
1 = Yes
2 = No
Text Congruency: Number of unique benefits presented in
superscript/subscript:_____
Image Congruency:
1 = incongruent (negative when discussing benefits)
2 = neutral
3 = congruent (positive when discussing benefits)
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Appendix E
Stigma and Relevance Study Instrument
Health Conditions Survey
Please mark the place you think best represents the stigma of each condition.
Stigma can be defined as “a mark of disgrace or infamy; a stain or reproach, as
on one’s reputation.”
Depression
No Stigma ____ ____ ____ ____ ____ ____ Very Strong Stigma
Asthma/other breathing problems
No Stigma ____ ____ ____ ____ ____ ____ Very Strong Stigma
High Cholesterol
No Stigma ____ ____ ____ ____ ____ ____ Very Strong Stigma
Schizophrenia
No Stigma ____ ____ ____ ____ ____ ____ Very Strong Stigma
Insomnia (inability to fall asleep)
No Stigma ____ ____ ____ ____ ____ ____ Very Strong Stigma
Fibromyalgia (nerve pain)
No Stigma ____ ____ ____ ____ ____ ____ Very Strong Stigma
Seasonal Allergies
No Stigma ____ ____ ____ ____ ____ ____ Very Strong Stigma
Acid Reflux
No Stigma ____ ____ ____ ____ ____ ____ Very Strong Stigma
Erectile Dysfunction
No Stigma ____ ____ ____ ____ ____ ____ Very Strong Stigma
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Now, please rate how relevant these conditions are for college students. (Would
college students be likely to suffer from these conditions?)
Depression
No Stigma ____ ____ ____ ____ ____ ____ Very Strong Stigma
Asthma/other breathing problems
Not relevant ____ ____ ____ ____ ____ ____ Very relevant
High Cholesterol
Not relevant ____ ____ ____ ____ ____ ____ Very relevant
Schizophrenia
Not relevant ____ ____ ____ ____ ____ ____ Very relevant
Insomnia (inability to fall asleep)
Not relevant ____ ____ ____ ____ ____ ____ Very relevant
Fibromyalgia (nerve pain)
Not relevant ____ ____ ____ ____ ____ ____ Very relevant
Seasonal Allergies
Not relevant ____ ____ ____ ____ ____ ____ Very relevant
Acid Reflux
Not relevant

____ ____ ____ ____ ____ ____ Very relevant
Erectile Dysfunction

Not relevant ____ ____ ____ ____ ____ ____ Very relevant
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Appendix F
Stigma and Relevance Study Results
Condition

Stigma
Mean

Depression
Asthma
Cholesterol
Schizophrenia
Insomnia
Fibromyalgia
Allergies
Acid Reflux
Erectile
Dysfunction

4.0488
1.8293
2.7073
4.9268
2.6250
2.2927
1.5854
2.3902
5.2195

Stigma
Standard
Deviation
1.20315
1.30197
1.47044
1.53932
1.29471
1.36462
0.89375
1.30150
1.42324

Relevance
Mean
4.3250
3.1750
2.9250
2.7000
4.8750
2.6500
4.6750
3.3250
2.5250

Relevance
Standard
Deviation
1.32795
1.48302
1.32795
1.39963
1.38096
1.12204
1.47435
1.14102
1.58499

Relevance –
Stigma
0.2762
1.3457
0.2177
-2.2268
2.2500
0.3273
3.0896
0.9348
0.16175

Bolded: Three most relevant/least stigmatized conditions; most appropriate for
college-age sample
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Appendix G
Composite Scores for Ad Persuasiveness
Source credibility= trustworthiness + expertise + experience + sociability +
celebrity + likability + demographic similarity + lifestyle similarity
For all but attractiveness:
2 = present
1 = unsure
0 = not present
For attractiveness:
2 = attractive
1 = average
0 = unattractive
Persuasiveness = (∑source credibility/ # primary or secondary actors) + number
of AIDA components - (# risks/#ben) - (seconds spent on risks/ seconds of ad)
Where:
# risks = risks in voice track + risks in text
# ben = benefits in voice track + benefits in text
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Appendix H
Composite Score Calculations
Ad
Advair 1
Advair 2
Advair 3
Advair 4
Lunesta
1
Lunesta
2
Lunesta
3
Nasonex
1
Nasonex
2

∑source
cred
52
13
13
14
12

#
actors
4
1
1
1
1

#AIDA #risks #ben risk
time
3
9
6
13
3
9
12
16
3
9
9
17
3
9
10
14
3
22
6
26

ad
time
60
60
61
60
54

Score

10

1

3

21

4

30

60

7.250

22

2

3

21

5

30

58

9.283

25

2

3

5

10

6

30

14.800

23

2

3

5

9

4

30

13.811

Bolded: Three most persuasive advertisements for each drug
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14.283
14.983
14.721
15.867
10.852

Appendix I
Pre-test Instrument
Age: _____________
Gender:
Male
Female
Race/Ethnicity:
White
African American
Hispanic/ Latino
Asian/Pacific Islander
Multi-racial
Other/ No answer
1. I have a lot of knowledge about how to select the best drug for a given condition
Strongly disagree
____ ____ ____ ____ ____ ____ ____ Strongly agree
2. I have a clear idea about which drug characteristics are really important in providing
me with maximum symptom relief and satisfaction.
Strongly disagree
____ ____ ____ ____ ____ ____ ____ Strongly agree
3. I do not have a clear idea about which drug characteristics are really important in
providing me with maximum symptom relief and satisfaction. (r)
Strongly disagree
____ ____ ____ ____ ____ ____ ____ Strongly agree
4. Please rate your level of knowledge of prescription drugs.
Not knowledgeable ____ ____ ____ ____ ____ ____
knowledgeable

____

Very

Instructions: For each of the statements below, please indicate to what extent the
statement is characteristic of you. If the statement is extremely uncharacteristic of you
(not at all like you) please write a "1" to the left of the question; if the statement is
extremely characteristic of you (very much like you) please write a "5" next to the
question. Of course, a statement may be neither extremely uncharacteristic nor
extremely characteristic of you; if so, please use the number in the middle of the scale
that describes the best fit. Please keep the following scale in mind as you rate each of
the statements below: 1 = extremely uncharacteristic; 2 = somewhat uncharacteristic; 3
= uncertain; 4 = somewhat characteristic; 5 = extremely characteristic.
1. I would prefer complex to simple problems.
1
2
3
4
5
2. I like to have the responsibility of handling a situation that requires a lot of thinking.
1
2
3
4
5
3. Thinking is not my idea of fun.
1
2
3
4
5
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4. I would rather do something that requires little thought than something that is sure to
challenge my thinking abilities?
1
2
3
4
5
5. I try to anticipate and avoid situations where there is a likely chance I will have to think
in depth about something.
1
2
3
4
5
6. I find satisfaction in deliberating hard and for long hours.
1
2
3
4
5
7. I only think as hard as 1 have to.
1
2
3
4
5
8. I prefer to think about small, daily projects to long-term ones?
1
2
3
4
5
9. I like tasks that require little thought once I've learned them?
1
2
3
4
5
10. The idea of relying on thought to make my way to the top appeals to me.
1
2
3
4
5
11. I really enjoy a task that involves coming up with new solutions to problems.
1
2
3
4
5
12. Learning new ways to think doesn't excite me very much?
1
2
3
4
5
13. I prefer my life to be filled with puzzles that I must solve.
1
2
3
4
5
14. The notion of thinking abstractly is appealing to me.
1
2
3
4
5
15. I would prefer a task that is intellectual, difficult, and important to one that is
somewhat important but does not require much thought.
1
2
3
4
5
16. 1 feel relief rather than satisfaction after completing a task that required a lot of
mental effort?
1
2
3
4
5
17. It's enough for me that something gets the job done; I don't care how or why it
works?
1
2
3
4
5
18. I usually end up deliberating about issues even when they do not affect me
personally.
1
2
3
4
5
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Appendix J
Post-test Instrument
(correct answers in bold)
Advair
1. Which of the following drugs did you see in an advertisement?
a) Singulair
b) Advair
c) Spiriva
d) Flovent
2. Advair treats:
a) depression
b) insomnia
c) allergies
d) asthma
3. One benefit of using Advair is that:
a) it contains two medicines in one
b) can be taken more than twice per day
c) clears allergies related to asthma
d) it is specially designed for older adults
4. Another benefit of using Advair is:
a) increases energy
b) can get first prescription free
c) the corticosteroids increase muscle mass
d) decreases risk of pneumonia
5. A drawback of Advair is that it can:
a) increase chances of osteoporosis
b) can cause insomnia
c) increase heart rate
d) causes halitosis
6. One risk associated with Advair is:
a) it can cause more colds
b) it can cause eye problems
c) it can cause bloody noses
d) it decrease sperm count
7. I feel very knowledgeable about Advair.
Strongly Disagree
____
Strongly agree

____

____

____

____

____

____

8. If a friend asked me about Advair, I could give them advice about whether or not
to take it.
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Strongly Disagree
____
Strongly agree

____

____

____

____

____

____

9. If I had to ask my doctor for Advair today, I would need to gather very little
information in order to make a wise decision.
Strongly Disagree
____
Strongly agree

____

____

____

____

____

____

10. I feel very confident about my ability to tell the difference in quality among
different drugs for asthma and COPD.
Strongly Disagree
____
Strongly agree

____

____

____

____

____

____

11. If I was suffering from asthma or COPD, the likelihood of me asking a doctor for
Advair would be…
Very low

____

____

____

____

____

____

____

Very high

12. If I was suffering from asthma or COPD, my willingness to take Advair would
be…
Very low

____

____

____

____

____

____

____

Very high

____

____

____

____

____

____

____

____

____

____

____

13. I am intrigued by Advair.
Strongly Disagree
____
Strongly agree

14. I’d like to know more about Advair.
Strongly Disagree
____
Strongly agree

____

15. Learning more about Advair would be useless. (r)
Strongly Disagree
____
Strongly agree

____

____

____

____

____

____

____

____

____

____

____

16. I’m a little curious about Advair.
Strongly Disagree
____
Strongly agree

____

Lunesta
Answer the questions according to the information presented in the advertisements.
1. Which of the following drugs did you see in an advertisement?
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a) Ambien
b) Sonata
c) Lunesta
d) Silenor
2. Lunesta treats:
a) depression
b) insomnia
c) allergies
d) asthma
3. One benefit of Lunesta is that it:
a) helps you get the restful sleep you need
b) clears up colds to help you sleep comfortably
c) fixes problems with sleepwalking
d) makes you feel happier
4. One benefit of Lunesta is that it:
a) cures restless leg syndrome so you can sleep
b) helps you sleep for at least 6 hours
c) is available without a prescription
d) has a free 7 night trial
5. One drawback of Lunesta is that:
a) may worsen depression in patients with depression
b) causes dry-mouth
c) can lower immune system
d) can make you sleep for 12 hours or more
6. When taking Lunesta:
a) you might gain weight
b) you might lose weight
c) your throat or tongue might swell
d) your muscles might feel sore
7. I feel very knowledgeable about Lunesta.
Strongly Disagree
____
Strongly agree

____

____

____

____

____

____

8. If a friend asked me about Lunesta, I could give them advice about whether or
not to take it.
Strongly Disagree
____
Strongly agree

____

____

____

____

____

____

9. If I had to ask my doctor for Lunesta today, I would need to gather very little
information in order to make a wise decision.
Strongly Disagree
____
Strongly agree

____

____
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____

____

____

____

10. I feel very confident about my ability to tell the difference in quality among
different drugs for insomnia.
Strongly Disagree
____
Strongly agree

____

____

____

____

____

____

11. If I was suffering from insomnia, the likelihood of me asking a doctor for Lunesta
would be…
Very low

____

____

____

____

____

____

____

Very high

12. If I was suffering from insomnia, my willingness to take Lunesta would be…
Very low

____

____

____

____

____

____

____

Very high

____

____

____

____

____

____

____

____

____

____

____

13. I am intrigued by Lunesta.
Strongly Disagree
____
Strongly agree

14. I’d like to know more about Lunesta.
Strongly Disagree
____
Strongly agree

____

15. Learning more about Lunesta would be useless. (r)
Strongly Disagree
____
Strongly agree

____

____

____

____

____

____

____

____

____

____

____

16. I’m a little curious about Lunesta.
Strongly Disagree
____
Strongly agree

____

Nasonex
1. Which of the following drugs did you see in an advertisement?
a) Allegra
b) Zyrtec
c) Claritin
d) Nasonex
2. Nasonex treats
a) depression
b) insomnia
c) allergies
d) asthma
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3. A benefit of Nasonex is that it:
a) relieves both indoor and outdoor allergies
b) relieves sinus headaches
c) available without a prescription
d) comes in dissolving tablet form
4. A risk of using Nasonex is:
a) blurred vision
b) increased chance of viral infection
c) increased heart rate
d) drowsiness
5. I feel very knowledgeable about Nasonex.
Strongly Disagree
____
Strongly agree

____

____

____

____

____

____

6. If a friend asked me about Nasonex, I could give them advice about whether or
not to take it.
Strongly Disagree
____
Strongly agree

____

____

____

____

____

____

7. If I had to ask my doctor for Nasonex today, I would need to gather very little
information in order to make a wise decision.
Strongly Disagree
____
Strongly agree

____

____

____

____

____

____

8. I feel very confident about my ability to tell the difference in quality among
different drugs for seasonal allergies.
Strongly Disagree
____
Strongly agree

____

____

____

____

____

____

9. If I was suffering from seasonal allergies, the likelihood of me asking a doctor for
Nasonex would be…
Very low

____

____

____

____

____

____

____

Very high

10. If I was suffering from seasonal allergies, my willingness to take Nasonex would
be…
Very low

____

____

____

____

____

____

____

Very high

____

____

____

____

____

____

11. I am intrigued by Nasonex.
Strongly Disagree
____
Strongly agree
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12. I’d like to know more about Nasonex.
Strongly Disagree
____
Strongly agree

____

____

____

____

____

____

13. Learning more about Nasonex would be useless. (r)
Strongly Disagree
____
Strongly agree

____

____

____

____

____

____

____

____

____

____

____

14. I’m a little curious about Nasonex.
Strongly Disagree
____
Strongly agree

____
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